Literature DB >> 26732302

Ossifying fibromyxoid tumor: morphology, genetics, and differential diagnosis.

Nina Schneider1, Cyril Fisher1, Khin Thway2.   

Abstract

Ossifying fibromyxoid tumor (OFMT) is a soft tissue neoplasm of uncertain differentiation and intermediate (rarely metastasizing) biologic potential, with typical morphologic features, of an encapsulated, lobulated tumor comprising uniform polygonal cells within fibromyxoid stroma, which is surrounded by or contains metaplastic bone, classically as a peripheral rim of lamellar bone. Ossifying fibromyxoid tumor can arise at almost any site, although most frequently occurs within the extremities and trunk. Although most behave in a benign fashion, tumors can rarely show atypical or malignant features. It is now established that OFMTs represent translocation-associated tumors, with up to 85% associated with recurrent gene rearrangements, mostly involving the PHF1 gene (including in typical, atypical, and malignant neoplasms), with EP400-PHF1 in approximately 40% of tumors, and ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions also described. Correct diagnosis is clinically important to ensure correct treatment and prognostication, both to avoid overdiagnosing OFMT as a malignant neoplasm such as osteosarcoma and also because of the propensity for aggressive behavior in a small number of OFMT. We review OFMT, with emphasis on the morphologic spectrum, recent molecular genetic findings, and the differential diagnosis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EP400-PHF1; Genetics; MEAF6-PHF1; Ossifying fibromyxoid tumor; Pathology; Sarcoma; ZC3H7B-BCOR

Mesh:

Year:  2015        PMID: 26732302     DOI: 10.1016/j.anndiagpath.2015.11.002

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  7 in total

Review 1.  What is new about the molecular genetics in matrix-producing soft tissue tumors? -The contributions to pathogenetic understanding and diagnostic classification.

Authors:  Yu-Chien Kao; Jen-Chieh Lee; Hsuan-Ying Huang
Journal:  Virchows Arch       Date:  2019-11-07       Impact factor: 4.064

2.  Expanding the molecular signature of ossifying fibromyxoid tumors with two novel gene fusions: CREBBP-BCORL1 and KDM2A-WWTR1.

Authors:  Yu-Chien Kao; Yun-Shao Sung; Lei Zhang; Chun-Liang Chen; Shih-Chiang Huang; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2016-08-26       Impact factor: 5.006

3.  Recurrent chromosomal translocations in sarcomas create a megacomplex that mislocalizes NuA4/TIP60 to Polycomb target loci.

Authors:  Nikita Avvakumov; Marie-Eve Lalonde; Nader Alerasool; Charles Joly-Beauparlant; Karine Jacquet; Amel Mameri; Deepthi Sudarshan; Jean-Philippe Lambert; Justine Rousseau; Catherine Lachance; Eric Paquet; Lara Herrmann; Samarth Thonta Setty; Jeremy Loehr; Marcus Q Bernardini; Marjan Rouzbahman; Anne-Claude Gingras; Benoit Coulombe; Arnaud Droit; Mikko Taipale; Yannick Doyon; Jacques Côté
Journal:  Genes Dev       Date:  2022-06-16       Impact factor: 12.890

4.  Ossifying fibromyxoid tumor of the trunk mimicking hydatid cyst: A case report.

Authors:  Nihed Abdessayed; Sarra Mestiri; Houssem Ammar; Ahlem Bdioui; Amine Chhaidar; Omar Toumi; Nozha Mhamdi; Rahul Gupta; Marwa Guerfela; Moncef Mokni
Journal:  Int J Surg Case Rep       Date:  2017-07-22

5.  Malignant ossifying fibromyxoid tumor of the calvaria: illustrative case.

Authors:  Jan T Hachmann; R Scott Graham
Journal:  J Neurosurg Case Lessons       Date:  2021-08-23

6.  Ossifying fibromyxoid tumor of the oral cavity: rare case report and long-term follow-up.

Authors:  Maria Eduarda Pérez-de-Oliveira; Thayná Melo de Lima Morais; Márcio Ajudarte Lopes; Oslei Paes de Almeida; Willie F P van Heerden; Pablo Agustin Vargas
Journal:  Autops Case Rep       Date:  2020-12-08

Review 7.  Ossifying Fibromyxoid tumor of soft parts in head and neck: case report and literature review.

Authors:  Ignacio A Velasco; Ran Zhang; Tiejun Li; Diancan Wang
Journal:  Diagn Pathol       Date:  2018-03-27       Impact factor: 2.644

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.